- Do you, or did you, own shares of American Renal Associates Holdings, Inc. (NYSE: ARA)?
- Did you purchase your shares pursuant and/or traceable to the April 21, 2016 initial public offering, or between April 21, 2016 and August 18, 2016, inclusive?
- Did you lose money in your investment?
Please contact Rigrodsky & Long, P.A. (“R & L”) to schedule a free consultation. You may call us or fill out our contact form so that we can call at your convenience. Your consultation will not create any obligation to use our services at any time.
R & L is investigating claims brought in a securities fraud class action complaint against American Renal Associates Holdings, Inc. ("American Renal") concerning whether American Renal and certain of the Company’s directors and/or officers made materially false and misleading statements and failed to disclose materially adverse facts between April 21, 2016 and August 18, 2016, inclusive, including those investors who acquired American Renal shares pursuant to or traceable to its initial public offering commenced on April 21, 2016 (the “Class Period”), concerning the Company’s business, operations and prospects. These misrepresentations and omissions artificially inflated the price of the Company's stock throughout the Class Period.